0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessObjectives To examine the benefit of the Tryton dedicated side branch (SB) stent compared with provisional stenting in the treatment of complex bifurcation lesions involving large SBs. Background The TRYTON Trial was designed to evaluate the utility of a dedicated SB stent to treat true bifurcation lesions involving large (≥2.5 mm by visual estimation) SBs. Patient enrolled in the trial had smaller SB diameters than intended (59% SB ≤2.25 mm by Core Lab QCA). The TRYTON Trial did not meet its primary endpoint due to an increased rate of peri‐procedural myocardial infarctions (MIs). Methods The TRYTON Trial randomized 704 patients to the Tryton SB stent with main vessel DES versus provisional SB treatment with main vessel DES. The rates of the primary end point of target vessel failure and the secondary powered end point of angiographic percent diameter stenosis in the SB at 9 months were assessed and compared between the two treatment strategies among patients with a SB ≥2.25 mm diameter at baseline determined by Core Lab QCA. Results Among the 704 patients enrolled in the TRYTON Trial, 289 patients (143 provisional and 146 Tryton stent; 41% of entire cohort) had a SB ≥2.25 mm. The primary end point of TVF was numerically lower in the Tryton group compared with the provisional group (11.3% vs. 15.6%, P = 0.38), and was within the non‐inferiority margin. No difference among the rates of clinically driven target vessel revascularization (3.5% vs. 4.3% P = 0.77) or cardiac death (0% both groups) were seen. In‐segment percent diameter stenosis of the SB was significantly lower in the Tryton group compared with the provisional group (30.4% vs. 40.6%, P = 0.004). Conclusions Analysis of the TRYTON Trial cohort of SB ≥2.25 mm supports the safety and efficacy of the Tryton SB stent compared with a provisional stenting strategy in the treatment of bifurcation lesions involving large SBs. © 2015 Wiley Periodicals, Inc.
Philippe Généreux, Annapoorna Kini, Maciej Lesiak, Indulis Kumsārs, Géza Fontos, Ton Slagboom, Imre Ungi, D. Christopher Metzger, Joanna J. Wykrzykowska, Pieter R. Stella, Antonio L. Bartorelli, William F. Fearon, Thierry Lefévre, Robert L. Feldman, Giuseppe Tarantini, Nicolas Bettinger, Girma Minalu Ayele, Laura LaSalle, Dominic P. Francese, Yoshinobu Onuma, Maik J. Grundeken, Héctor M. García‐García, Linda L. Laak, Donald E. Cutlip, Aaron V. Kaplan, Patrick W. Serruys, Martin B. Leon (2015). Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized <scp>TRYTON</scp> bifurcation study. Catheterization and Cardiovascular Interventions, 87(7), pp. 1231-1241, DOI: 10.1002/ccd.26240.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2015
Authors
27
Datasets
0
Total Files
0
Language
English
Journal
Catheterization and Cardiovascular Interventions
DOI
10.1002/ccd.26240
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access